"Simvastatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.
| Descriptor ID |
D019821
|
| MeSH Number(s) |
D02.455.426.559.847.638.400.900 D04.615.638.400.900
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Simvastatin".
Below are MeSH descriptors whose meaning is more specific than "Simvastatin".
This graph shows the total number of publications written about "Simvastatin" by people in this website by year, and whether "Simvastatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1998 | 1 | 1 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 3 | 0 | 3 |
| 2004 | 2 | 1 | 3 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 1 | 3 |
| 2007 | 3 | 1 | 4 |
| 2008 | 2 | 2 | 4 |
| 2009 | 3 | 1 | 4 |
| 2010 | 2 | 1 | 3 |
| 2011 | 3 | 1 | 4 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 4 | 6 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 1 | 3 |
| 2016 | 2 | 2 | 4 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Simvastatin" by people in Profiles.
-
Cross-linking Proteomics Indicates Effects of Simvastatin on the TLR2 Interactome and Reveals ACTR1A as a Novel Regulator of the TLR2 Signal Cascade. Mol Cell Proteomics. 2019 09; 18(9):1732-1744.
-
Relation of statin use with non-melanoma skin cancer: prospective results from the Women's Health Initiative. Br J Cancer. 2016 Feb 02; 114(3):314-20.
-
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis. 2013 Dec; 231(2):371-7.
-
Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS One. 2011; 6(12):e28813.
-
Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol. 2011 Nov-Dec; 5(6):474-82.
-
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci. 2009 Oct 28; 29(43):13543-56.
-
Simvastatin with or without ezetimibe in familial hypercholesterolemia (the ENHANCE trial). Curr Atheroscler Rep. 2009 Mar; 11(2):81-2.
-
Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Metab Syndr Relat Disord. 2008 Jun; 6(2):149-52.
-
Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes. 2008 Mar; 57(3):714-23.
-
Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol. 2007 Nov 01; 100(9):1397-9.